Exelixis, Inc. (EXEL): Price and Financial Metrics


Exelixis, Inc. (EXEL): $18.40

0.21 (+1.15%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add EXEL to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

EXEL POWR Grades


  • Value is the dimension where EXEL ranks best; there it ranks ahead of 96.18% of US stocks.
  • EXEL's strongest trending metric is Quality; it's been moving up over the last 179 days.
  • EXEL ranks lowest in Momentum; there it ranks in the 4th percentile.

EXEL Stock Summary

  • For EXEL, its debt to operating expenses ratio is greater than that reported by merely 9.57% of US equities we're observing.
  • EXEL's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 11.22% of US stocks.
  • Over the past twelve months, EXEL has reported earnings growth of 124.83%, putting it ahead of 83.89% of US stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Exelixis Inc are CYTK, EYEN, DCPH, MXL, and VERU.
  • EXEL's SEC filings can be seen here. And to visit Exelixis Inc's official web site, go to www.exelixis.com.

EXEL Valuation Summary

  • In comparison to the median Healthcare stock, EXEL's EV/EBIT ratio is 69.28% higher, now standing at 49.6.
  • Over the past 243 months, EXEL's price/sales ratio has gone down 21.5.
  • EXEL's price/earnings ratio has moved up 72.6 over the prior 243 months.

Below are key valuation metrics over time for EXEL.

Stock Date P/S P/B P/E EV/EBIT
EXEL 2021-08-31 5.2 3.0 64.2 49.6
EXEL 2021-08-30 5.2 3.0 64.5 49.8
EXEL 2021-08-27 5.3 3.0 65.1 50.3
EXEL 2021-08-26 5.2 2.9 63.8 49.2
EXEL 2021-08-25 5.2 2.9 63.4 48.8
EXEL 2021-08-24 5.2 2.9 63.4 48.9

EXEL Growth Metrics

    Its 2 year cash and equivalents growth rate is now at 53.47%.
  • The year over year net income to common stockholders growth rate now stands at -77.96%.
  • The 5 year net income to common stockholders growth rate now stands at 249.99%.
EXEL's revenue has moved up $579,376,000 over the prior 34 months.

The table below shows EXEL's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 1,434.97 400.804 231.063
2021-09-30 1,253.882 337.645 164.285
2021-06-30 1,156.551 272.276 94.041
2021-03-31 1,030.853 192.452 64.77
2020-12-31 987.538 208.982 111.781
2020-09-30 957.796 333.71 152.136

EXEL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EXEL has a Quality Grade of B, ranking ahead of 93.02% of graded US stocks.
  • EXEL's asset turnover comes in at 0.549 -- ranking 297th of 563 Business Services stocks.
  • BBSI, QNST, and ROL are the stocks whose asset turnover ratios are most correlated with EXEL.

The table below shows EXEL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.549 0.961 0.128
2021-06-30 0.525 0.960 0.071
2021-03-31 0.486 0.961 0.045
2020-12-31 0.479 0.963 0.088
2020-09-30 0.479 0.961 0.129
2020-06-30 0.520 0.963 0.248

EXEL Price Target

For more insight on analysts targets of EXEL, see our EXEL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $31.77 Average Broker Recommendation 1.46 (Moderate Buy)

EXEL Stock Price Chart Interactive Chart >

Price chart for EXEL

EXEL Price/Volume Stats

Current price $18.40 52-week high $23.52
Prev. close $18.19 52-week low $15.50
Day low $18.00 Volume 2,026,362
Day high $18.52 Avg. volume 2,431,169
50-day MA $21.38 Dividend yield N/A
200-day MA $19.78 Market Cap 5.90B

Exelixis, Inc. (EXEL) Company Bio


Exelixis is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. The company was founded in 1994 and is based in San Francisco, California.


EXEL Latest News Stream


Event/Time News Detail
Loading, please wait...

EXEL Latest Social Stream


Loading social stream, please wait...

View Full EXEL Social Stream

Latest EXEL News From Around the Web

Below are the latest news stories about Exelixis Inc that investors may wish to consider to help them evaluate EXEL as an investment opportunity.

Exelixis: The 'Rinse, Wash, And Repeat' Trade

Consistency is the hallmark of the unimaginative.”― Oscar Wilde We revisit an old friend named Exelixis (EXEL) today after the company's very solid fourth quarter earnings report last week. Exelixis continues to ramp up sales of its flagship product, CABOMETYX, which is now in the $1 billion plus 'blockbuster' category...

Bret Jensen on Seeking Alpha | February 21, 2022

Does Exelixis (NASDAQ:EXEL) Have A Healthy Balance Sheet?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Yahoo | February 20, 2022

Exelixis, Inc. 2021 Q4 - Results - Earnings Call Presentation

The following slide deck was published by Exelixis, Inc. in conjunction with their 2021 Q4 earnings call....

SA Transcripts on Seeking Alpha | February 18, 2022

Exelixis (EXEL) Q4 Earnings & Revenues Beat, Cabometyx Strong

Exelixis (EXEL) beats on both earnings and revenues in the fourth quarter. Both figures increase on a year-over-year basis.

Yahoo | February 18, 2022

Exelixis (EXEL) Tops Q4 Earnings and Revenue Estimates

Exelixis (EXEL) delivered earnings and revenue surprises of 314.29% and 26.31%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 17, 2022

Read More 'EXEL' Stories Here

EXEL Price Returns

1-mo -18.58%
3-mo -8.82%
6-mo 7.85%
1-year -18.15%
3-year -8.14%
5-year -4.91%
YTD 0.66%
2021 -8.92%
2020 13.90%
2019 -10.42%
2018 -35.30%
2017 103.89%

Continue Researching EXEL

Here are a few links from around the web to help you further your research on Exelixis Inc's stock as an investment opportunity:

Exelixis Inc (EXEL) Stock Price | Nasdaq
Exelixis Inc (EXEL) Stock Quote, History and News - Yahoo Finance
Exelixis Inc (EXEL) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4503 seconds.